<DOC>
	<DOCNO>NCT00480597</DOCNO>
	<brief_summary>Development active second-line treatment option metastatic breast cancer patient previously pre-treated anthracyclines taxanes neoadjuvant , adjuvant palliative setting . For randomisation arm , 47 patient include . The trial perform 2-stage phase II study accord optimal design Simon overall response rate primary objective . Study Design : Arm A Gemcitabine 1000 mg/m2 d1 , 8 ; Vinorelbine 25 mg/m2 d1 , 8 q 3 week Arm B Gemcitabine 1000 mg/m2 d1 , 8 ; Cisplain 30 mg/m2 d1 , 8 q 3 week Arm C Gemcitabine 1000 mg/m2 d1 , 8 ; Capecitabine 1650 mg/m2 oral d1-14 q 3 week</brief_summary>
	<brief_title>Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm metastatic breast cancer All patient require give write informed consent Only one prior chemotherapy metastatic breast cancer allow . This clinical trial design test efficacy secondline chemotherapy . Antracyclinepretreatment aduvant palliative first line therapy Bidimensionally measurable lesion outside previous radiation field . Age &gt; = 18 year Karnofsky Performance status &gt; = 70 % Adequate heamatological , renal , cardiac hepatic function No radiation measurable lesion study allow . Only bone metastasis Active infection Previous treatment one study drug Application cytotoxic chemotherapy Insufficent renal function ( creatinine clearance &lt; 60ml/min ) Known DPD deficiency clinically unstable brain metastasis pregancy lactation primary malignancy ( carcinomainsitu cervix adequately treat basal cell cancer skin ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>gemcitabine</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>pretreated metastatic breast cancer</keyword>
</DOC>